Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Operations: 2013-2025

Historic Cash from Operations for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to -$6.1 million.

  • Fortress Biotech's Cash from Operations rose 69.54% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.1 million, marking a year-over-year increase of 35.30%. This contributed to the annual value of -$80.2 million for FY2024, which is 37.46% up from last year.
  • Latest data reveals that Fortress Biotech reported Cash from Operations of -$6.1 million as of Q3 2025, which was up 77.83% from -$27.6 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Cash from Operations ranged from a high of -$6.1 million in Q3 2025 and a low of -$47.8 million during Q4 2022.
  • In the last 3 years, Fortress Biotech's Cash from Operations had a median value of -$21.8 million in 2024 and averaged -$23.8 million.
  • Per our database at Business Quant, Fortress Biotech's Cash from Operations slumped by 116.06% in 2022 and then surged by 69.54% in 2025.
  • Quarterly analysis of 5 years shows Fortress Biotech's Cash from Operations stood at -$38.7 million in 2021, then dropped by 23.64% to -$47.8 million in 2022, then increased by 26.98% to -$34.9 million in 2023, then spiked by 63.05% to -$12.9 million in 2024, then skyrocketed by 69.54% to -$6.1 million in 2025.
  • Its Cash from Operations was -$6.1 million in Q3 2025, compared to -$27.6 million in Q2 2025 and -$19.6 million in Q1 2025.